Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
US7714013B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2006 |
| Grant date | May 11, 2010 |
| Priority date | — |
| Expiry date | Aug 28, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D453/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.